- Home
- SUIG vs AVTX Comparison
SUIG vs AVTX Comparison
Compare SUIG & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUIG | AVTX |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.0M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SUIG | AVTX |
|---|---|---|
| Price | $1.69 | $17.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $5.75 | ★ $32.29 |
| AVG Volume (30 Days) | ★ 1.3M | 342.5K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,608,807.00 | $192,000.00 |
| Revenue This Year | $14.32 | N/A |
| Revenue Next Year | $80.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.58 | N/A |
| 52 Week Low | $1.13 | $3.39 |
| 52 Week High | $8.66 | $20.72 |
Technical Indicators
Market Signals| Indicator | SUIG | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.40 |
| Support Level | N/A | $18.58 |
| Resistance Level | N/A | $19.97 |
| Average True Range (ATR) | 0.00 | 1.28 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 0.00 | 15.88 |
Price Performance
Historical ComparisonAbout SUIG Sui Group Holdings Limited
Sui Group Holdings Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).